| Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFIC (REV 5-93) | | | IMERCE PATENT AND TRADEMARK OFFICE | attorney's docket number PU60791 |
|--|---|---|---------------------------------------|--|
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) | | | | U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) |
| | | TATIONAL APPLICATION NO. US 2004/008025 | INTERNATIONAL FILING DATE 17-Mar-2004 | PRIORITY DATE CLAIMED 17-Mar-2004 |
| TITLE OF INVENTION M3 Muscarinic Acetylchoine Receptor Antagonists | | | | |
| APPLICANT(S) FOR DO/EO/US Jakob Busch-Petersen, Anthony William James Cooper, Dramane Ibrahim Laine, Michael R. Palovich, , Zehong Wan, Hongxing Yan, Chongjie Zhu | | | | |
| $Applicant \ herewith \ submits \ to \ the \ United \ States \ Designated/Elected \ Office \ (DO/EO/US) \ the \ following \ items \ and \ other \ information:$ | | | | |
| [x] This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. [] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. [x] This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). [x] The US has been elected (Article 31). | | | | |
| | [x] A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. [] is transmitted herewith (required only if not transmitted by the International Bureau). b. [] has been transmitted by the International Bureau. c. [x] is not required, as the application was filed in the United States Receiving Office (RO/US). | | | |
| 6. | [] | A translation of the International Application into English (35 U.S.C. 371(c)(2)). | | |
| 7. | [] | Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. [] are transmitted herewith (required only if not transmitted by the International Bureau). b. [] have been transmitted by the International Bureau. c. [] have not been made; however, the time limit for making such amendments has NOT expired. d. [] have not been made and will not be made. | | |
| 9. 10. | [] | A translation of the amendments to the claims under PCT Article 19 (35 U.S. C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). a. [x] was submitted as part of the international application under Rule 4.17(iv). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). | | |
| Items 11. to 16. below concern other document(s) or information included: | | | | |
| 12. | [] | An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449. A copy of the assignment document; A FIRST preliminary amendment. (Add claim to priority via Preliminary Amendment for US originating cases only) | | |
| 17. i | [] [x] [x] [x] | A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. Declaration and Power of Attorney. An Abstract on a separate sheet of paper. Copy of Form PCT/ISA/210. | | |